Altamira Therapeutics Ltd Quick Ratio (CYTO) starting from the second quarter 2025 to second quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Altamira Therapeutics Ltd   (NASDAQ: CYTO)

Altamira Therapeutics Ltd 's Quick Ratio

CYTO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2025, Quick Ratio fell to 0 a new company low.

Within Major Pharmaceutical Preparations industry 597 other companies have achieved higher Quick Ratio than Altamira Therapeutics Ltd in second quarter 2025. While Quick Ratio total ranking in the second quarter 2025 has deteriorated compared to the prior quarter from 2889 to 3422.

Explain Quick Ratio?
How much Cash & cash equivalents CYTO´s has?
What are CYTO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CYTO Quick Ratio (Jun 30 2025)
Q4		 (Dec 31 2024)
Q3		 (Jun 30 2024)
Q2		 (Dec 31 2023)
Q1		 0
Q4
Y / Y Current Liabilities Change 34.34 % -61.19 % -40.76 % -92.64 % -93.62 %
Y / Y Cash & cash equivalent Change -99.39 % 1703.09 % -89.4 % 4309 % 3610.17 %
Quick Ratio MRQ 0 1.81 0.12 0.52 0.69
CYTO's Total Ranking # 3422 # 2889 # 5513 # 3045 # 6702
Seq. Current Liabilities Change 116.32 % 4.84 % -62.71 % 58.88 % -37.52 %
Seq. Cash & cash equivalent Change -99.62 % 1425.66 % -91.08 % 18.84 % 1014.78 %



Quick Ratio second quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 598
Healthcare Sector # 1213
Overall Market # 5798


Quick Ratio Statistics
High Average Low
3.72 0.84 0
(Dec 31 2020)   (Dec 31 2022)




Financial Statements
Altamira Therapeutics Ltd 's Current Liabilities $ 1 Millions Visit CYTO's Balance sheet
Altamira Therapeutics Ltd 's Cash & cash equivalent $ 0 Millions Visit CYTO's Balance sheet
Source of CYTO's Sales Visit CYTO's Sales by Geography


Cumulative Altamira Therapeutics Ltd 's Quick Ratio

CYTO's Quick Ratio for the trailling 12 Months

CYTO Quick Ratio

 (Jun 30 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Dec 31 2023)
12 Months		 0
12 Months
Y / Y Current Liabilities TTM Growth -83.54 % -90.46 % -90.94 % -92.3 % -51.4 %
Y / Y Cash & cash equivalent TTM Growth 37.85 % 242.06 % 120.98 % 2998.54 % 15.75 %
Quick Ratio TTM 0.49 0.71 0.35 0.44 0.06
Total Ranking TTM # 4094 # # # #
Seq. Current Liabilities TTM Growth 9.03 % -20.48 % -7.86 % -79.4 % -36.82 %
Seq. Cash & cash equivalent TTM Growth -25.41 % 64.08 % -27.27 % 54.87 % 85.09 %

Quick ratio ranking by company, industry and sector >> Back to CYTO Financial Strength Comparisons >> Go to Compare CYTO Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2025 to $1.19 millions, cumulative Quick Ratio decreased to 0.49 above the CYTO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 493 other companies have achieved higher Quick Ratio than Altamira Therapeutics Ltd . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2024 from to 4094.

Explain Quick Ratio?
How much Cash & cash equivalents CYTO´s has?
What are CYTO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 494
Healthcare Sector # 1005
Within the Market # 4094


trailing twelve months Quick Ratio Statistics
High Average Low
0.69 0.21 0
(Dec 31 2023)   (Dec 31 2022)




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Neonc Technologies Holdings Inc   0.01 $ 0.125  Millions$ 14.477  Millions
Accustem Sciences Inc   0.01 $ 0.031  Millions$ 4.148  Millions
Prophase Labs Inc   0.01 $ 0.171  Millions$ 25.626  Millions
Lunai Bioworks Inc   0.01 $ 0.093  Millions$ 18.399  Millions
Oncotelic Therapeutics Inc 0.00 $ 0.088  Millions$ 19.287  Millions
One World Products Inc 0.00 $ 0.014  Millions$ 3.425  Millions
Altamira Therapeutics Ltd 0.00 $ 0.004  Millions$ 1.194  Millions
Propanc Biopharma Inc 0.00 $ 0.012  Millions$ 5.578  Millions
Scienture Holdings Inc 0.00 $ 0.015  Millions$ 7.813  Millions
Bioadaptives Inc 0.00 $ 0.003  Millions$ 1.408  Millions
Bioxytran Inc 0.00 $ 0.003  Millions$ 2.783  Millions

Date modified: 2026-09-02T17:46:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.